Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers Health $1 Billion Eucalyptus Acquisition Fuels Global Expansion Dreams
08:50am, Thursday, 19'th Feb 2026
The positive movement follows the announcement of a definitive agreement to acquire Eucalyptus, a digital health leader, which is expected to enhance Hims & Hers' international presence.
Hims & Hers is spending more than $1 billion in a push to expand globally
08:08am, Thursday, 19'th Feb 2026
Shares of Hims & Hers Health rallied in early Thursday trading, after the health-and-wellness platform announced a deal to buy an Australia-based telehealth provider.
Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint
08:04am, Thursday, 19'th Feb 2026
Hims & Hers (NYSE:HIMS) announced on Thursday that it has entered a definitive agreement to acquire Australian digital health company Eucalyptus in a deal...
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal
07:31am, Thursday, 19'th Feb 2026
Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.
Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider
07:25am, Thursday, 19'th Feb 2026
Hims & Hers Health will buy Eucalyptus, an Australian digital health company, in a deal valued at $1.15 billion.
Hims & Hers Q4 Earnings Preview: What To Expect From Upcoming Report
07:04am, Thursday, 19'th Feb 2026
Hims and Hers (HIMS) is set to report fourth-quarter fiscal 2025 results after market close on Feb. 23. Analysts expect earnings to decline, while revenue may see
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal
07:00am, Thursday, 19'th Feb 2026
Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion
06:10am, Thursday, 19'th Feb 2026
Hims & Hers Health said on Thursday it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion, as the U.S. telehealth platform seeks to broaden its personali
Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
06:04am, Thursday, 19'th Feb 2026
Online telehealth company Hims & Hers Health , seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of weight-loss pills that drew swift bl
Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform
06:00am, Thursday, 19'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an in
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
06:47pm, Wednesday, 18'th Feb 2026
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $15.84, marking a -2.64% move from the previous day.
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
10:15am, Wednesday, 18'th Feb 2026
LOS ANGELES, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Healt
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
09:06am, Wednesday, 18'th Feb 2026
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk
11:04am, Tuesday, 17'th Feb 2026
Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.
3 Once-In-A-Decade REIT Opportunities To Win Big
07:15am, Tuesday, 17'th Feb 2026
AI is crushing digital businesses, and capital is starting to rotate out of tech. Meanwhile, many REITs trade at 30% discounts to NAV with ~5% yields. We highlight three anti-AI real asset plays that
